DIFFERENTIAL DIAGNOSTIC FEATURES OF HYPERTENSION IN METABOLIC SYNDROME AND HYPERTENSIVE DISEASE

DOI: https://doi.org/10.29296/25877305-2019-04-01
Download full text PDF
Issue: 
4
Year: 
2019

Professor Yu. Uspensky(1, 3), MD; Ya. Bulavko(1); Professor M. Galagudza(2), MD, Corresponding Member of the Russian Academy of Sciences; Associate Professor Yu. Fominykh(3), Candidate of Medical Sciences; A. Gnutov(1) 1-Saint Petersburg State Pediatric Medical University 2-V.A. Almazov National Medical Research Center, Saint Petersburg 3-Acad. I.P. Pavlov First Saint Petersburg State Medical University

Metabolic syndrome (MS) can rightly be considered as an extra-nosological clinical phenomenon and a starting pathobiochemical and dysmetabolic status of the body, which is subsequently often transformed into cardiovascular and endocrinological diseases and contributes to the damage to target organs, and also frequently to the development of complications with high mortality rates. The paper highlights pathobiochemical and clinical differential diagnostic criteria for hypertension in both MS and hypertensive disease (HD), as well as the characteristics of the formation of MS components in childhood. It explains the necessity of elaborating algorithms and criteria for the differential diagnosis of hypertension in HD and MS, which will help the clinician to diagnose and prescribe the most adequate therapy. Since MS is a reversible condition, correction of dysmetabolic disorders in the early stages contributes not only to lowering blood pressure, but also to preventing their evolution into HD and improving the metabolic profile, by preventing the development of type 2 diabetes.

Keywords: 
cardiology
endocrinology
metabolic syndrome
hypertension
hypertensive disease
differential diagnosis



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Serdechno-sosudistye zabolevanija. Informatsionnyj bjulleten' VOZ. 17 maja 2017 [El. resurs]. [Cardiovascular diseases. Information sources of WHO. 17 May. 2017 [Electronic resource]]. Av. from: http: who.int/ru/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  2. Mule G., Nardi E., Cottone S. et al. Influence of metabolic syndrome on hypertension-related target organ damage // J. Int. Med. – 2005; 257 (6): 503–13. DOI: 10.1111/j.1365-2796.2005.01493.x
  3. Fominyh Ju.A., Shabrov A.V., Uspenskij Ju.P. i dr. Funktsional'nyj zapor u patsientov s metabolicheskim sindromom // Eksperim. i klin. gastroenterol. – 2017; 7 (143): 151–4 [Fominykh Yu.A., Shabrov A.V., Uspenskiy Yu.P. et al. Functional constipation at patients with metabolic syndrome // Eksperimental’naya i klinicheskaya gastroenterologiya. – 2017; 7 (143): 151–4 (in Russ.)].
  4. Uspenskij Ju.P., Fominyh Ju.A., Sousova Ja.V. i dr. Gastroenterologicheskie projavlenija metabolicheskogo sindroma // Vrach. – 2018; 29 (12): 3–8 [Uspensky Yu., Fominykh Yu., Sousova Ya. et al. Gastrointestinal manifestations o fmetabolic syndrome // Vrach. – 2018; 29 (12): 3–8 (in Russ.)]. DOI: 10.29296/25877305-2018-12-01.
  5. Lang G.F. Gipertonicheskaja bolezn' / L.: Medgiz, 1950; 496 c. [Lang G. Hypertension / L.: Medgiz, 1950; 496 p. (in Russ.)].
  6. Fominyh Ju.A. Metabolicheskij sindrom: istoricheskie aspekty izuchenija problemy // Dnevnik kazanskoj meditsinskoj shkoly. – 2018; 3 (21): 208–13 [Fominykh Yu.A. Metabolic syndrome: historical aspects problem’s studying // Dnevnik kazanskoi meditsinskoi shkoly. – 2018; 3 (21): 208–13 (in Russ.)].
  7. Simmons R., Alberti K., Gale E. et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation // Diabetologia. – 2010; 53 (4): 600–5. DOI:10.1007/s00125-009-1620-4.
  8. International Diabetes Federation (IDF) Consensus Definition in Russian. Available from: http://www.docstoc.com/docs/454620/Metabolic-Syndrome-International-Diabetes-Federation--consensus-definition-In-Russian
  9. Alberti K., Eckel R., Grundy S. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the study of Obesity // Circulation. – 2009; 120: 1640–5. DOI: 10.1161/CIRCULATIONAHA.109.192644.
  10. Parikh R., Mohan V. Changing Definitions of metabolic syndrome // Indian J. Endocrinol. Metabol. – 2012; 6 (1): 7. DOI: 10.4103/2230-8210.91175.
  11. Perova N.V., Metel'skaja V.A., Oganov V.G. i dr. Patogeneticheskie osnovy metabolicheskogo sindroma kak sostojanija vysokogo riska ateroskleroticheskih zabolevanij // Mezhd. med. zhurn. Klinika. Diagnostika. Lechenie. – 2001; 7 (3): 38–45. [Perova N., Metelskaya V., Oganov V., et al. Patogeneticheskie osnovy metabolicheskogo sindroma kak sostoyaniya vysokogo riska ateroskleroticheskikh zabolevanii // Mezhdunarodniy medicinskiy zhurnal. Klinika. Diagnostika. Lechenie. – 2001; 7 (3): 38–45 (in Russ.)].
  12. Butrova S.A. Metabolicheskij sindrom: patogenez, klinika, diagnostika, podhody k lecheniju // Rus. med. zhurn. – 2001; 9 (2): 56–60 [Butrova S.A. Metabolicheskii sindrom: patogenez, klinika, diagnostika, podkhody k lecheniyu // Russkiy medicinskiy zhurnal. – 2001; 9 (2): 56–60 (in Russ.)].
  13. Kraja A., Chasman D., North K. et al. Pleiotropic genes for metabolic syndrome and inflammation // Molecular genetics and metabolism. – 2014; 112 (4): 317–38. DOI: 10.1016/j.ymgme.2014.04.007.
  14. Vikulova O.K. Protivorechija i konsensusy metabolicheskogo sindroma. Po mat-lam IV Mezhd. kongr. «Prediabet i metabolicheskij sindrom», Madrid, 6–9 aprelja 2011 g. [Vikulova O.K. Protivorechiya i konsensusy metabolicheskogo sindroma. Po materialam IV mezhdunarodnogo kongressa «Prediabet i metabolicheskii sindrom», Madrid, 6–9 april 2011 (in Russ.)].
  15. Kaur J. A comprehensive review on metabolic syndrome // Cardiology research and practice. – 2014; 2014: 1–22. DOI: 10.1155/2014/943162
  16. Festa A., D’Agostino R. Jr., Howard G. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS) // Circulation – 2000; 102 (1): 42–7.
  17. Ishikawa S., Kayaba K., Gotoh T. et al. Metabolic syndrome and C-reactive protein in the general population // Circ. J. – 2007; 71 (1): 26–31.
  18. Shagalova N.Ja. Insulinorezistentnost' – pol'za ili vred? // Sovremennye problemy nauki i obrazovanija. – 2016; 2: 89 [Shagalova N.Ya. Insulin resistance – advantage or harm? // Sovremennye problem nauki i obrazovaniya. – 2016; 2: 89 (in Russ.)].
  19. Pashentseva A.V., Verbovoj A.F., Sharonova L.A. Insulinorezistent- nost' v terapevticheskoj klinike // Ozhirenie i metabolizm. – 2017; 14 (2): 9–17 [Pashentseva A.V., Verbovoi A.F., Sharonova L.A. Insulin resistance in therapeutic clinic // Ozhirenieimetabolizm. – 2017; 14 (2): 9–17 (in Russ.)]. DOI: 10.14341/OMET201729-17.
  20. Romantsova T.I., Dedov I.I., Kuznetsov I.S. Endokannabinoidnaja sistema: struktura i potentsial'nye vozmozhnosti v reguljatsii massy tela // Ozhirenie i metabolizm. – 2006; 4: 2–11 [Romantsova T.I., Dedov I.I., Kuznetsov I.S. Endokannabinoidnaya sistema: struktura i potentsial’nye vozmozhnosti v regulyatsii massy tela // Ozhirenie i metabolizm. – 2006; 4: 2–11 (in Russ.)].
  21. Pomorska D., do-Rego J., do-Rego J. et al. Opioid and cannabinoid system in food intake // Curr. Pharm. Design. – 2016; 22 (10): 1361–70.
  22. Kearney P., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data // Lancet. – 2005; 365 (9455): 217–23. DOI: 10.1016/S0140-6736(05)17741-1.
  23. Reynolds K., Chen J., He J. Global disparities of hypertension prevalence and control // Circulation. – 2016; 134: 441–50. DOI: 10.1161/CIRCULATIONAHA.115.018912.
  24. Shirokov E.A. Suslina Z.A., Fonjakin A.V. i dr. Prakticheskaja kardionevrologija / M.: IMA-PRESS, 2012; 1064 c. [Shirokov E.A., Suslina Z.A., Fonyakin A.V. et al. Practical cardioneurology / M.: IMA-PRESS. 2012; 1064 p. (in Russ.)].
  25. van Rooy M., Pretorius E. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke // Thromb. Res. – 2015; 135 (3): 434–42. DOI: 10.1016/j.thromres.2014.12.030.
  26. Taddei S., Virdis A., Ghiadoni L. et al. The role of endothelium in human hypertension // Curr. Opin. Nephrol. Hypertens. – 1998; 7 (2): 203–9. DOI: 10.1097/00041552-199803000-00010.
  27. Banerjee A., Silver L., Heneghan C. et al. Population-based comparison of risk factors for ischaemic stroke versus acute coronary syndromes: identical twins or distant relatives? // Cerebrovasc. Dis. – 2008; 25: 16–8. DOI: 10.1161/CIRCULATIONAHA.115.016424.
  28. Filippova O.V. Krizovoe techenie arterial'noj gipertenzii na dogospital'nom etape: algoritm vedenija patsienta // Rus. med. zhurn. – 2018; 1 (2): 76–81 [Filippova O.V. Hypertensive crisis at the prehospital stage: patient management algorithm // Russkii meditsinskii zhurnal. – 2018; 1(2): 76-81 (in Russ)].
  29. Nedogoda S.V., Vertkin A.L., Baranova E.I. i dr. Algoritmy vedenija patsienta s gipertonicheskim krizom / SPb: Obscheross. obsch. organizats. sodejstvija profilakt. i lecheniju arterial'noj gipertenzii «Antigipertenzivnaja Liga», 2015; 32 s. [Nedogoda S.V., Vertkin A.L., Baranova E.I. etal. Algoritmyvedeniyapatsienta s gipertonicheskimkrizom / SPb.: Obshcherossiiskaya obshchestvennaya organizatsiya sodeistviya profilaktike i lecheniyu arterial’noi gipertenzii «Antigipertenzivnaya Liga», 2015; 32 s (in Russ.)].
  30. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome // J. Mol. Med. – 2008; 86 (6): 729. DOI: 10.1007/s00109-008-0343-1.
  31. Olsen M., Angell S., Asma S. et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension // Lancet. – 2016; 388 (10060): 2665–712. DOI: 10.1016/S0140-6736(16)31134-5.
  32. Bojtsov S.A. Chto my znaem o patogeneze arterial'noj gipertenzii // Consilium Medicum. – 2004; 6 (5): 315–9 [Boitsov S.A. Chto my znaem o patogeneze arterial’noi gipertenzii // Consilium Medicum. – 2004; 6 (5): 315–9 (in Russ.)].
  33. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret G.B., Munroe P.B. et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk // Nature. – 2011; 478: 103–9. DOI: 10.1038/nature10405.
  34. Timasheva Y., Nasibullin T., Zakirova A. et al. Multilocus association analysis identifies genetic predictors of essential hypertension // Eur. Heart J. – 2018; 39 (1): 292. DOI: 10.1093/eurheartj/ehy565.P1534.
  35. Sergeeva V.V., Rodionova A.Ju. Sovremennyj podhod k otsenke arterial'noj gipertenzii v sochetanii s metabolicheskimi narushenijami // Arterial'naja gipertenzija. – 2013; 19 (5): 397–404 [Sergeeva V.V., Rodionova A.Yu. Modern approach to the assessment of hypertension and metabolic disorders // Arterial’naya gipertenziya. – 2013; 19 (5): 397–404 (in Russ.)]. DOI: 10.18705/1607-419X-2013-19-5-397-404.
  36. Blagosklonskaja Ja.V., Shljahto E.V., Krasil'nikova E.I. Metabolicheskij serdechno-sosudistyj sindrom // Rus. med. zhurn. – 2001; 9 (2): 67–71 [Blagosklonskaya Ya.V., Shlyakhto E.V., Krasil’nikova E.I. Metabolicheskii serdechno-sosudistyi sindrom // Russkii meditsinskii zhurnal. – 2001; 9 (2): 67–71 (in Russ.)].
  37. Soleimani M. Insulin resistance and hypertension: new insights // Kidney Int. – 2015; 87 (3): 497–9. DOI: 10.1038/ki.2014.392.
  38. Strjuk R.I., Tsyganok N.Ju. Nejrogumoral'nye mehanizmy patogeneza metabolicheskogo sindroma // Kardiologija. – 2006; 4: 54–9 [Stryuk R.I., Tsyganok N.Yu. Neurohomoral mechanisms of the pathogenesis of the metabolic syndrome // Kardiologiya. – 2006; 4: 54–9 (in Russ.)].
  39. Drapkina O.M., Korneeva O.N., Ivashkin V.T. Aktivatsija simpaticheskoj nervnoj sistemy pri ozhirenii. Kak povlijat' na energeticheskij gomeostaz? // Arterial'naja gipertenzija. – 2011; 17 (2): 102–7 [Drapkina, O.M., Korneeva, O.N., Ivashkin, V.T. Sympathetic hyperactivity in obesity. How to affect the energy homeostasis? // Arterial’naya gipertenziya. – 2011; 17 (2): 102–7 (in Russ.)].
  40. Konradi A.O. Ozhirenie, simpaticheskaja giperaktivnost' i arterial'naja gipertenzija – est' li svjaz'? // Arterial'naja gipertenzija. – 2006; 12 (2): 131–40 [Conrady A.O. Obesity, sympathetic nervous system, and hypertension – are they connected? // Arterial’naya Gipertenziya (Arterial Hypertension). – 2006; 12 (2): 131–40 (in Russ.)]. https://doi.org/10.18705/1607-419X-2006-12-2-131-140.
  41. Mudritskaja T.N. Arterial'naja gipertenzija i metabolicheskij sindrom // Krymskij ter. zhurn. – 2009; 1: 19–21 [Mudritskaya T.N. Hypertension and metabolic syndrome // Krymskij terapevticheskij zhurnal. – 2009; 1: 19–21 (In Russ)].
  42. Zhang X., Lassila M., Cooper M. et al. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors // Hypertension. – 2004; 43 (2): 276–81. DOI:10.1161/01.HYP.0000113628.94574.0.
  43. Osei S., Price D., Fisher N. et al. Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans // Hypertension. – 1999; 33 (1): 559–64.
  44. Oganov R.G., Aleksandrov A.A. Giperinsulinemija i arterial'naja gipertonija: vozvraschajas' k vyvodam United Kingdom Prospective Diabetes Study // Rus. med. zhurn. – 2002; 10 (11): 486–91 [Oganov R., Aleksandrov A. Giperinsulinemiya i arterial’naya gipertoniya: vozvrashchayas’ k vyvodam United Kingdom Prospective Diabetes Study // Russkij medicinskij zhurnal. – 2002; 10(11): 486–91 (in Russ.)].
  45. Libby P., Ridker P., Maseri A. Inflammation and atherosclerosis // Circulation. – 2002; 105 (9): 1135–43.
  46. Weyer C., Funahashi T., Tanaka S. et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia // J. Clin. Endocrinol. Metabol. – 2001; 86 (5): 1930–5. DOI: 10.1210/jcem.86.5.7463.
  47. Voropaj L.A., Voropaj N.G., Gribanova A.S. i dr. Osobennosti metabolicheskogo sindroma u podrostkov // Ros. vestn. perinatol. i pediat. – 2017; 62 (4): 160 [Voropaj L., Voropaj N., Gribanova A. et al. Osobennosti metabolicheskogo sindroma u podrostkov // Rossijskij vestnik perinatologii i pediatrii. – 2017; 62 (4): 160 (in Russ.)].
  48. Gerasimova A.S., Olejnikov V.E. Arterial'naja gipertonija, assotsiirovannaja s metabolicheskim sindromom: osobennosti techenija i porazhenija organov-mishenej // Izvestija vysshih uchebnyh zavedenij. Povolzhskij region. Meditsinskie nauki. – 2008; 3: 88–101 [Gerasimova A., Olejnikov V. Arterial’naya gipertoniya, associirovannaya s metabolicheskim sindromom: osobennosti techeniya i porazheniya organov-mishenej // Izvestiya vysshih uchebnyh zavedenij. Povolzhskij region. Medicinskie nauki. – 2008; 3: 88–101 (in Russ)].
  49. Ionov M.V., Zvartau N.E., Konradi A.O. Sovmestnye klinicheskie rekomendatsii ESH/ESC 2018 po diagnostike i vedeniju patsientov s arterial'noj gipertenziej: pervyj vzgljad // Arterial'naja gipertenzija – 2018; 24 (3): 351–8 [Ionov M., Zvartau N., Konradi A. First look at new 2018 joint ESH/ESC. Guidelines on diagnosis and management of hypertension // Arterial’naya gipertenziya – 2018; 24 (3): 351–8 (in Russ.)]. DOI: 10.18705/1607-419X-2018-24-3-351-358.